Employers who've been reeling from near double-digit health cost increases the past three years can expect more of the same in 2027, according to new projections from benefits consultant Aon.
Why it matters: Companies and their workers are locked in one of the most sustained periods of health care inflation in decades — and the trend lines are sure to intensify affordability concerns.
Walmart posted its worst U.S. same-store sales growth in more than six years, raising questions about the health of the American consumer, even as the company raised its outlook for the full fiscal year.
Why it matters: As the world's largest retailer, Walmart has long been viewed as a bellwether for the economy and the health of the consumer.
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial.
Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards.
President Trump announced Wednesday he's nominating White House aide Heidi Overton to lead the Food and Drug Administration.
Why it matters: The agency was left in turmoil after the exit of former commissioner Marty Makary earlier this year, threatening the stability of U.S. drug development.
The American Medical Association is out with a new framework for physicians' role in the age of AI, provided first to Axios, that insists doctors remain central to patient care.
Why it matters: The debate over whether AI will supplant doctors in clinical care is heating up, but the AMA has remained adamant that humans not only must remain in the loop but can't be replaced.
